ABP
Abpro CorporationNASDAQHealthcareAs of 2026-04-04
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
-0.03
P/S
2.35
EV/EBITDA
-0.02
DCF Value
$-16.17
FCF Yield
-3169.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
-55.2%
Operating Margin
-7950.8%
Net Margin
-7670.5%
ROE
83.2%
ROA
-824.3%
ROIC
93.8%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $0.00 | $-1.7M | $-0.63 |
| Q2 2025 | $0.00 | $-3.0M | $-1.56 |
| Q1 2025 | $0.00 | $-3.9M | $-2.40 |
| Q4 2024 | $183.0K | $-5.5M | $-17.70 |
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
-0.00
Abpro Holdings, Inc., a biotechnology company, engages in developing antibody therapeutics for patients with immuno-oncology, ophthalmology, and autoimmunity issues. Its platform DiversImmune addresses a bottleneck in the antibody therapeutics industry. Its lead product candidates include ABP-100 for the treatment of breast, gastric, and colorectal cancers; and ABP-201 for the treatment of vascular diseases of the eye. The company has a strategic partnership with Abpro Bio Co. Ltd and NJCTTQ. The company was formerly known as Abpro Corporation and changed its name to Abpro Holdings, Inc. in November 2024. Abpro Holdings, Inc. was incorporated in 2004 and is headquartered in Woburn, Massachusetts.